Impact BioMedical (IBO) Registration Filing summary

Company overview and business model

• Operates as a holding company focused on drug discovery, wellness, and intellectual property development through subsidiaries and partnerships.

• Key areas: universal therapeutic drug platform, sugar substitute (Laetose), and multi-use fragrance (3F).

• Business model centers on licensing, co-development, and royalty agreements with pharma and consumer goods companies.

• Owns or controls majority stakes in several subsidiaries, including Global BioLife, Impact BioLife Science, Global Biomedical, and Sweet Sense.

• Actively seeks new technologies and partners to expand its IP portfolio.

Financial performance and metrics

• For the six months ended June 30, 2024: revenue $0, net loss $1.88M, cash $2,000, total assets $44.1M, liabilities $17.7M, equity $26.4M.

• For the year ended December 31, 2023: net loss $4.41M, compared to $7.26M in 2022; no revenue in 2023.

• Operating losses and negative cash flows from operations and investing activities for the past two years.

• Ongoing concern warning due to recurring losses and limited liquidity; relies on related party debt financing.

Use of proceeds and capital allocation

• Expects ~$5.1M in net proceeds from IPO (up to $5.9M if over-allotment exercised).

• Plans to allocate ~20% to R&D, with the remainder for licensing, commercialization, working capital, and general corporate purposes.

• Proceeds may also be used for debt repayment and offering costs.